BI 671800 ED in Steroid-naive Asthmatic Patients
Public ClinicalTrials.gov record NCT01092143. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 6 week study to investigate the effectiveness and safety of BI 671800 ED in patients with asthma who do not take inhaled corticosteroids.
Study identification
- NCT ID
- NCT01092143
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 389 participants
Conditions and interventions
Conditions
Interventions
- BI 671800 Drug
- Fluticasone propionate placebo Drug
- Fluticasone propionate Drug
- BI 671800 Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 17, 2010
- Primary completion
- Mar 25, 2011
- Completion
- Mar 25, 2011
- Last update posted
- May 30, 2022
2010 – 2011
United States locations
- U.S. sites
- 40
- U.S. states
- 21
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1268.17.01043 Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| 1268.17.01009 Boehringer Ingelheim Investigational Site | Cypress | California | — | — |
| 1268.17.01006 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1268.17.01040 Boehringer Ingelheim Investigational Site | Palmdale | California | — | — |
| 1268.17.01024 Boehringer Ingelheim Investigational Site | San Jose | California | — | — |
| 1268.17.01003 Boehringer Ingelheim Investigational Site | Stockton | California | — | — |
| 1268.17.01015 Boehringer Ingelheim Investigational Site | Colorado Springs | Colorado | — | — |
| 1268.17.01001 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 1268.17.01016 Boehringer Ingelheim Investigational Site | Lakewood | Colorado | — | — |
| 1268.17.01033 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1268.17.01045 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 1268.17.01036 Boehringer Ingelheim Investigational Site | Normal | Illinois | — | — |
| 1268.17.01025 Boehringer Ingelheim Investigational Site | South Bend | Indiana | — | — |
| 1268.17.01005 Boehringer Ingelheim Investigational Site | Iowa City | Iowa | — | — |
| 1268.17.01034 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 1268.17.01014 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1268.17.01030 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1268.17.01027 Boehringer Ingelheim Investigational Site | Novi | Michigan | — | — |
| 1268.17.01032 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 1268.17.01010 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1268.17.01037 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1268.17.01022 Boehringer Ingelheim Investigational Site | Bozeman | Montana | — | — |
| 1268.17.01008 Boehringer Ingelheim Investigational Site | Bellevue | Nebraska | — | — |
| 1268.17.01011 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1268.17.01004 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1268.17.01038 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1268.17.01042 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1268.17.01007 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1268.17.01031 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 1268.17.01039 Boehringer Ingelheim Investigational Site | Fort Mill | South Carolina | — | — |
| 1268.17.01026 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1268.17.01029 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1268.17.01049 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1268.17.01019 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1268.17.01012 Boehringer Ingelheim Investigational Site | El Paso | Texas | — | — |
| 1268.17.01023 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1268.17.01048 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1268.17.01028 Boehringer Ingelheim Investigational Site | New Braunfels | Texas | — | — |
| 1268.17.01035 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1268.17.01047 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01092143, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 30, 2022 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01092143 live on ClinicalTrials.gov.